Literature DB >> 10913381

Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA).

M J Maanen1, C J Smeets, J H Beijnen.   

Abstract

N,N',N" -triethylenethiophosphoramide (thioTEPA) is a trifunctional alkylating agent with a broad spectrum of antitumour activity developed in the 1950s. The drug is now experiencing renewed interest as it appears to be one of the most effective anticancer drugs in high dose regimens. Despite many years of experience with thioTEPA, pharmacologic data are incomplete and controversy remains with respect to the dose-dependent pharmacokinetics of thioTEPA. In recent years greater insight has been obtained into the metabolism of thioTEPA, but there is still a gap between the total urinary excretion of thioTEPA and metabolites and the alkylating activity. In vivo and in vitro studies show that alkylation of DNA by thioTEPA can follow two pathways, but it remains unclear which pathway represents the precise mechanism of action. The currently available sensitive analytical methods for thioTEPA and its metabolites can be used to elucidate the many questions that still exist even so many years after its introduction. An overview is given of the chemistry, pharmacology, clinical use and toxicity of thioTEPA as well as its pharmacokinetics and analytical methods for thioTEPA and its metabolites. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913381     DOI: 10.1053/ctrv.2000.0170

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  16 in total

1.  Some physicochemical properties of the antitumor drug thiotepa and its metabolite tepa as obtained by density functional theory (DFT) calculations.

Authors:  Djaffar Kheffache; Ourida Ouamerali
Journal:  J Mol Model       Date:  2010-02-14       Impact factor: 1.810

Review 2.  PARP-1 and its associated nucleases in DNA damage response.

Authors:  Yijie Wang; Weibo Luo; Yingfei Wang
Journal:  DNA Repair (Amst)       Date:  2019-07-08

3.  Effects of thioTEPA chemotherapy on cognition and motor coordination.

Authors:  Tyler C Alexander; Frederico Kiffer; Thomas Groves; Julie Anderson; Jing Wang; Abdallah Hayar; Michelle T Chen; Analiz Rodriguez; Antiño R Allen
Journal:  Synapse       Date:  2019-03-14       Impact factor: 2.562

4.  Chemotherapy drug thioTEPA exacerbates stress-induced anhedonia and corticosteroid responses but not impairment of hippocampal cell proliferation in adult mice.

Authors:  Courtney L Wilson; E Todd Weber
Journal:  Behav Brain Res       Date:  2012-09-04       Impact factor: 3.332

5.  A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.

Authors:  A D Huitema; R A Mathôt; M M Tibben; S Rodenhuis; J H Beijnen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

6.  Mechanisms and kinetics of thiotepa and tepa hydrolysis: DFT study.

Authors:  Hedieh Torabifard; Alireza Fattahi
Journal:  J Mol Model       Date:  2012-02-14       Impact factor: 1.810

7.  KDM6B promotes PARthanatos via suppression of O6-methylguanine DNA methyltransferase repair and sustained checkpoint response.

Authors:  Mingming Yang; Chenliang Wang; Mi Zhou; Lei Bao; Yanan Wang; Ashwani Kumar; Chao Xing; Weibo Luo; Yingfei Wang
Journal:  Nucleic Acids Res       Date:  2022-06-24       Impact factor: 19.160

8.  Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.

Authors:  Sarah Anand; Samantha Thomas; Kelly Corbet; Cristina Gasparetto; Gwynn D Long; Richard Lopez; Ashley K Morris; David A Rizzieri; Keith M Sullivan; Anthony D Sung; Stefanie Sarantopoulos; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-17       Impact factor: 5.742

9.  Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites.

Authors:  Daniel R McNeill; Wing Lam; Theodore L DeWeese; Yung-Chi Cheng; David M Wilson
Journal:  Mol Cancer Res       Date:  2009-05-26       Impact factor: 5.852

10.  OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.

Authors:  Kathryn Evans; JianXin Duan; Tara Pritchard; Connor D Jones; Lisa McDermott; Zhaohui Gu; Cara E Toscan; Narimanne El-Zein; Chelsea Mayoh; Stephen W Erickson; Yuelong Guo; Fanying Meng; Donald Jung; Komal S Rathi; Kathryn G Roberts; Charles G Mullighan; Chi-Sheng Shia; Tillman Pearce; Beverly A Teicher; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2019-04-23       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.